Ranbaxy Laboratories has entered into an exclusive marketing agreement for India and Nepal with CD Pharma for Inersan, a patented probiotic preparation.Inersan is used for the treatment of dental problems like periodontitis, gingivitis and halitosis. According to a release issued by Ranbaxy today, there is no drug available for the treatment of these dental problems in the country today.Sanjeev I. Dani, senior vice president and regional director (Asia & CIS), Ranbaxy, said: "In the post-patent era, we are driven by the need to in-licence differentiated products, and the introduction of Inersan tablets consolidates Ranbaxy's position in the dental segment."Kanwaldeep Chadha, country manager, CD Pharma India, said: "Internationally, Inersan has shown good clinical results across trials done in oral inflammatory conditions of different etiologies. Clinical trials conducted in India have also given encouraging results. We plan to introduce trial-backed-first-of-its-kind probiotic products in the near future."CD Pharma India, which is based in New Delhi, is the Asian affiliate of US-based VSL Pharmaceuticals Inc.
